Grail as a molecular determinant for the functions of the tumor suppressor p53 in tumorigenesis

Cell Death and Differentiation

Volumn 20, Issue 5, 2013, Pages 732-743

  Chen, Y C ^a   Chan, J Y H ^a,b   Chiu, Y L ^a   Liu, S T ^a   Lozano, G ^c   Wang, S L ^a   Ho, C L ^a,b   Huang, S M ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE RELATED TO ANERGY IN LYMPHOCYTE PROTEIN; GLYCOPROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL LEVEL; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NEGATIVE FEEDBACK; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P21; G1 PHASE CELL CYCLE CHECKPOINTS; HELA CELLS; HUMANS; MICE; PROMOTER REGIONS, GENETIC; PROTEIN INTERACTION DOMAINS AND MOTIFS; RATS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 84877585835     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.1     Document Type: Article

References (31)

1. Zuckerman V, Wolyniec K, Sionov RV, Haupt S, Haupt Y. Tumour suppression by p53: the importance of apoptosis and cellular senescence. J Pathol 2009; 219: 3-15.
2. Jiang L, Sheikh MS, Huang Y. Decision making by p53: life versus death. Mol Cell Pharmacol 2010; 2: 69-77.
3. May P, May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 1999; 18: 7621-7636.
4. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer 2009; 9: 724-737.
5. Anandasabapathy N, Ford GS, Bloom D, Holness C, Paragas V, Seroogy C et al. GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4\+ T cells. Immunity 2003; 18: 535-547.
6. Seroogy CM, Soares L, Ranheim EA, Su L, Holness C, Bloom D et al. The gene related to anergy in lymphocytes, an E3 ubiquitin ligase, is necessary for anergy induction in CD4 T cells. J Immunol 2004; 173: 79-85.
7. Whiting CC, Su LL, Lin JT, Fathman CG. GRAIL: a unique mediator of CD4 T-lymphocyte unresponsiveness. FEBS J 2011; 278: 47-58.
8. Heissmeyer V, Macian F, Im SH, Varma R, Feske S, Venuprasad K et al. Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat Immunol 2004; 5: 255-265.
9. Nurieva RI, Zheng S, Jin W, Chung Y, Zhang Y, Martinez GJ et al. The E3 ubiquitin ligase GRAIL regulates T cell tolerance and regulatory T cell function by mediating T cell receptor-CD3 degradation. Immunity 2010; 32: 670-680.
10. Lin JT, Lineberry NB, Kattah MG, Su LL, Utz PJ, Fathman CG et al. Naive CD4 T cell proliferation is controlled by mammalian target of rapamycin regulation of GRAIL expression. J Immunol 2009; 182: 5919-5928.
11. Su LL, Iwai H, Lin JT, Fathman CG. The transmembrane E3 ligase GRAIL ubiquitinates and degrades CD83 on CD4 T cells. J Immunol 2009; 183: 438-444.
12. Lineberry N, Su L, Soares L, Fathman CG. The single subunit transmembrane E3 ligase gene related to anergy in lymphocytes (GRAIL) captures and then ubiquitinates transmembrane proteins across the cell membrane. J Biol Chem 2008; 283: 28497-28505.
13. Soares L, Seroogy C, Skrenta H, Anandasabapathy N, Lovelace P, Chung CD et al. Two isoforms of otubain 1 regulate T cell anergy via GRAIL. Nat Immunol 2004; 5: 45-54.
14. Nakamichi S, Senga Y, Inoue H, Emi A, Matsuki Y, Watanabe E et al. Role of the E3 ubiquitin ligase gene related to anergy in lymphocytes in glucose and lipid metabolism in the liver. J Mol Endocrinol 2009; 42: 161-169.
15. MacKenzie DA, Seroogy CM. Sustained expression of GRAIL during hematopoiesis results in dysregulated differentiation. Acta Haematol 2009; 122: 230-237.
16. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
17. Gartel AL, Najmabadi F, Goufman E, Tyner AL. A role for E2F1 in Ras activation of p21(WAF1/CIP1) transcription. Oncogene 2000; 19: 961-964.
18. Billon N, Carlisi D, Datto MB, van Grunsven LA,Watt A, Wang XF et al. Cooperation of Sp1 and p300 in the induction of the CDK inhibitor p21WAF1/CIP1 during NGF-mediated neuronal differentiation. Oncogene 1999; 18: 2872-2882.
19. Kardassis D, Papakosta P, Pardali K, Moustakas A. c-Jun transactivates the promoter of the human p21(WAF1/Cip1) gene by acting as a superactivator of the ubiquitous transcription factor Sp1. J Biol Chem 1999; 274: 29572-29581.
20. Koutsodontis G, Tentes I, Papakosta P, Moustakas A, Kardassis D. Sp1 plays a critical role in the transcriptional activation of the human cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by the p53 tumor suppressor protein. J Biol Chem 2001; 276: 29116-29125.
21. Liu PY, Chan JY, Lin HC, Wang SL, Liu ST, Ho CL et al. Modulation of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by Zac1 through the antagonistic regulators p53 and histone deacetylase 1 in HeLa Cells. Mol Cancer Res 2008; 6: 1204-1214.
22. Pang LY, Scott M, Hayward RL, H Mohammed, Whitelaw CB, Smith GC et al. p21(WAF1) is component of a positive feedback loop that maintains the p53 transcriptional program. Cell Cycle 2011; 10: 932-950.
23. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9: 400-414.
24. Huang W, Wang SL, Lozano G, de Crombrugghe B. cDNA library screening using the SOS recruitment system. Biotechniques 2001; 30: 94-98; 100.
25. Momand J, Wu HH, Dasgupta G. MDM2-master regulator of the p53 tumor suppressor protein. Gene 2000; 242: 15-29.
26. Huang SM, Schonthal AH, Stallcup MR. Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1. Oncogene 2001; 20: 2134-2143.
27. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K et al. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J 1999; 18: 1223-1234.
28. Didenko VV, Wang X, Yang L, Hornsby PJ. Expression of p21(WAF1/CIP1/SDI1) and p53 in apoptotic cells in the adrenal cortex and induction by ischemia/reperfusion injury. J Clin Invest 1996; 97: 1723-1731.
29. Akimzhanov A, Krenacs L, Schlegel T, Klein-Hessling S, Bagdi E, Stelkovics E et al. Epigenetic changes and suppression of the nuclear factor of activated T cell 1 (NFATc1) promoter in human lymphomas with defects in immunoreceptor signaling. Am J Pathol 2008; 172: 215-224.
30. Huang SM, Huang SP, Wang SL, Liu PY. Importin alpha1 is involved in the nuclear localization of Zac1 and the induction of p21(WAF1/CIP1) by Zac1. Biochem J 2007; 402: 359-366.
31. Ma H, Shang Y, Lee DY, Stallcup MR. Study of nuclear receptor-induced transcription complex assembly and histone modification by chromatin immunoprecipitation assays. Methods Enzymol 2003; 364: 284-296.